140 related articles for article (PubMed ID: 10828712)
21. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum alpha-hydroxybutyrate dehydrogenase in patients with ovarian carcinoma.
Kikuchi Y; Momose E; Kizawa I; Kuki E; Kato K
Acta Obstet Gynecol Scand; 1985; 64(7):553-6. PubMed ID: 4082930
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
24. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer.
Cobellis L; Reis FM; Luisi S; Danero S; Pirtoli L; Scambia G; Petraglia F
J Soc Gynecol Investig; 2004 May; 11(4):203-6. PubMed ID: 15120692
[TBL] [Abstract][Full Text] [Related]
25. Analysis of serum lactic dehydrogenase levels and its isoenzymes in ovarian dysgerminoma.
Fujii S; Konishi I; Suzuki A; Okamura H; Okazaki T; Mori T
Gynecol Oncol; 1985 Sep; 22(1):65-72. PubMed ID: 4018662
[TBL] [Abstract][Full Text] [Related]
26. LDH and LDH isoenzymes in ovarian dysgerminoma.
Levato F; Martinello R; Campobasso C; Porto S
Eur J Gynaecol Oncol; 1995; 16(3):212-5. PubMed ID: 7664770
[TBL] [Abstract][Full Text] [Related]
27. [Concentration of soluble ligand for receptor CD30 (sCD30L)--marker of apoptosis in women with ovarian tumor].
Mielczarek-Palacz A; Kondera-Anasz Z; Sikora J; Sodowski K; Switała J; Kubina R
Ginekol Pol; 2009 Jul; 80(7):494-7. PubMed ID: 19697811
[TBL] [Abstract][Full Text] [Related]
28. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
29. FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary.
Rzepka-Górska I; Chudecka-Głaz A; Kosmowska B
Endocr Relat Cancer; 2004 Jun; 11(2):315-21. PubMed ID: 15163306
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
32. Serum lactic dehydrogenase and primary carcinoma of the ovary.
Younis JS; Zeevi D; Hadani PE; Anteby SO
Gynecol Obstet Invest; 1989; 28(1):47-50. PubMed ID: 2777134
[TBL] [Abstract][Full Text] [Related]
33. Dysgerminoma and serum lactic dehydrogenase levels.
Awais GM
Obstet Gynecol; 1983 Jan; 61(1):99-101. PubMed ID: 6823354
[TBL] [Abstract][Full Text] [Related]
34. Serum lactic dehydrogenase: a tumor marker of ovarian dysgerminoma in a female pseudohermaphrodite.
Pode D; Kopolovic S; Gimmon Z
Gynecol Oncol; 1984 Sep; 19(1):110-3. PubMed ID: 6469085
[TBL] [Abstract][Full Text] [Related]
35. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
37. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors.
Healy DL; Burger HG; Mamers P; Jobling T; Bangah M; Quinn M; Grant P; Day AJ; Rome R; Campbell JJ
N Engl J Med; 1993 Nov; 329(21):1539-42. PubMed ID: 8413476
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
40. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
